How to buy Mirati Ther stock (MRTX)

Mirati Ther is a biotechnology business based in the US. Mirati Ther shares (MRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Mirati Ther employs 587 staff and has a trailing 12-month revenue of around $38.2 million.

Our top picks for where to buy Mirati Ther stock

Buy Mirati Ther stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Mirati Ther stock price (NASDAQ: MRTX)

Use our graph to track the performance of MRTX stocks over time.

Mirati Ther shares at a glance

• Key figures

Information last updated 2024-03-10.

52-week range	$58.54 - $59.46
50-day moving average more info button	$57.93
200-day moving average more info button	$45.92
Wall St. target price	$64.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-12.18

Is it a good time to buy Mirati Ther stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Mirati Ther financials

Revenue TTM	$38.2 million
Gross profit TTM	$-519,791,000
Return on assets TTM	-39.3%
Return on equity TTM	-69.95%
Profit margin	0%
Book value	$13.50
Market Capitalization more info button	$4.1 billion

TTM: trailing 12 months

Mirati Ther share dividends

We're not expecting Mirati Ther to pay a dividend over the next 12 months.

Have Mirati Ther's shares ever split?

Mirati Ther's shares were split on a 1:50 basis on 2 July 2013 . So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Mirati Ther shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Mirati Ther shares which in turn could have impacted Mirati Ther's share price.

Mirati Ther share price volatility

Over the last 12 months, Mirati Ther's shares have ranged in value from as little as $58.54 up to $59.46. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mirati Ther's is 0.77. This would suggest that Mirati Ther's shares are less volatile than average (for this exchange).

Mirati Ther overview

Mirati Therapeutics, Inc. , a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd.

Frequently asked questions

What percentage of Mirati Ther is owned by insiders or institutions?
Currently 1.715% of Mirati Ther shares are held by insiders and 117.761% by institutions. How many people work for Mirati Ther?
Latest data suggests 587 work at Mirati Ther. When does the fiscal year end for Mirati Ther?
Mirati Ther's fiscal year ends in December. Where is Mirati Ther based?
Mirati Ther's address is: 3545 Cray Court, San Diego, CA, United States, 92121 What is Mirati Ther's ISIN number?
Mirati Ther's international securities identification number is: US60468T1051 What is Mirati Ther's CUSIP number?
Mirati Ther's Committee on Uniform Securities Identification Procedures number is: 60468T105